RESEARCH ARTICLE

Initial Experience with a Wireless Ultrasound-Guided Vacuum-Assisted Breast Biopsy Device

E-Ryung Choi¹, Boo-Kyung Han¹ *, Eun Sook Ko¹, Eun Young Ko¹, Ji Soo Choi¹, Eun Yoon Cho², Seok Jin Nam³

¹ Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, ² Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, ³ Department of General Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

* bkhan@skku.edu

Abstract

Objective
To determine the imaging characteristic of frequent target lesions of wireless ultrasound (US)-guided, vacuum-assisted breast biopsy (Wi-UVAB) and to evaluate diagnostic yield, accuracy and complication of the device in indeterminate breast lesions.

Materials and Methods
From March 2013 to October 2014, 114 women (age range, 29–76 years; mean age, 50.0 years) underwent Wi-UVAB using a 13-gauge needle (Mammotome Elite¹; Devicor Medical Products, Cincinnati, OH, USA). In 103 lesions of 96 women with surgical (n = 81) or follow-up (n = 22) data, complications, biopsy procedure, imaging findings of biopsy targets and histologic results were reviewed.

Results
Mean number of biopsy cores was 10 (range 4–25). Nine patients developed moderate bleeding. All lesions were suspicious on US, and included non-mass lesions (67.0%) and mass lesions (33.0%). Visible calcifications on US were evident in 57.3% of the target lesions. Most of the lesions (93.2%) were nonpalpable. Sixty-six (64.1%) were malignant [ductal carcinoma in situ (DCIS) rate, 61%] and 12 were high-risk lesions (11.7%). Histologic underestimation was identified in 11 of 40 (27.5%) DCIS cases and in 3 of 9 (33.3%) high-risk lesions necessitating surgery. There was no false-negative case.

Conclusion
Wi-UVAB is very handy and advantageous for US-unapparent non-mass lesions to diagnose DCIS, especially for calcification cases. Histologic underestimation is unavoidable; still, Wi-UVAB is safe and accurate to diagnose a malignancy.
**Introduction**

Percutaneous breast biopsy became an alternative to surgical biopsy for imaging-detected or palpable breast masses. Accordingly, the needle biopsy has evolved from the Tru-Cut biopsy technique to vacuum-assisted breast biopsy (VAB), with the goal of minimizing a wrong diagnosis. VAB provides larger tissue samples with consistent quality. The advantages of VAB have been reported as a lower mistargeting rate and a lower underestimation rate of cancer, compared with a Tru-Cut biopsy using a 14-gauge needle [1–4].

However, conventional VAB with an 8- to 14-gauge needle is cumbersome due to the large equipment including a connecting line and the requirement for more time to prepare this equipment. Additionally, the cost of conventional VAB is much higher than for the Tru-Cut biopsy.

To overcome these disadvantages, a new wireless ultrasound (US)-guided VAB device (Wi-UVAB) has been introduced. The Mammotome Elite® (Devicor Medical Products, Cincinnati, OH, USA) automatically transports the acquired tissue into a single chamber. The device is easy to handle because of the lack of a connecting line and no additional time is required to prepare the equipment.

To our knowledge, only one study has evaluated the usefulness of this new Wi-UVAB device since its introduction. The diagnostic accuracy and success rate are unclear. The purpose of this study was to determine the imaging characteristics of frequent target lesions of Wi-UVAB and to evaluate diagnostic yield, accuracy and device-related complications in breast lesions.

**Materials and Methods**

Between March 2013 and December 2014, 114 consecutive female subjects (age range, 29–76 years; mean age, 50.0 years) underwent Wi-UVAB for 122 breast lesions using Mammotome Elite® with a 13-gauge needle. We retrospectively reviewed the medical records and imaging findings to determine the biopsy indications, complications and core and final pathological diagnosis. Eighteen patients with 19 lesions were excluded as follow-up US was not available or less than 6 months. The final study population consisted of 103 lesions in 96 women.

Our institutional (Samsung Medical Center [SMC]) review board approved our study (SMC 2014-07-118-001) with a waiver of the requirement for informed consent.

**Biopsy procedure**

Because our hospital is a tertiary referred hospital, our breast clinic is enriched by complicated cases including cases with imaging-pathologic discordance after the first biopsy and cases deemed to be difficult in US-guided Tru-Cut biopsy. After the review of outside US images and targeted US for suspected area, we recommended Wi-UVAB in the lesions that were seemingly difficult to target with Tru-Cut gun biopsy.

All biopsies were guided using a model IU 22 high-resolution US machine equipped with a 5- to 12-MHz linear transducer (Philips Medical System, Bothell, WA, USA). The biopsies were performed by one of four radiologists with 4 to 17 years of experience in breast sonography and intervention. The patients lay in the supine or oblique supine position. After visualization of the lesion using US, the skin entrance was determined for needle advancement parallel to the US probe. Local anesthesia was administered before the biopsy from the skin entrance to the lesion using 3 to 8 mL of lidocaine mixed with 1:105 diluted epinephrine. The Mammotome Elite® needle with a bladed tip was directly inserted either through or just subjacent to the lesion. For the first pass, the cutter automatically rotated to sample both the target lesion and adjacent tissues. For the next pass, we rotated the needle shaft based on the relationship between the needle and lesion position. The needle was usually rotated from the 9- to 3-o’clock...
position until adequate tissue was collected in the collection cup. The procedure was completed after specimen mammography when the target showed calcifications on mammography. The new needle was used for each biopsy when there were more than two suspicious mass in a patient. Manual compression was applied for 5 to 10 min to ensure hemostasis. Details of the biopsy procedure, including the reasons for use of this device instead of an automated gun, technical difficulties, core number, and complications were recorded. Bleeding longer than 20 min after the biopsy was considered as a complication. Severe pain terminating the procedure was also considered as a complication.

On the basis of the imaging findings, a metal clip was placed at the discretion of the radiologist performing the procedure. Criteria for clip deployment were that the postbiopsy ultrasound images demonstrate poor visualization of the target lesion due to removal. When requested by the surgeon, preoperative localization using intra-lesional carbon marking or wire insertion was performed.

Surgery was performed when the pathology revealed a malignancy, such as ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), or other invasive carcinoma. Patients with high-risk lesions, such as atypical ductal hyperplasia (ADH) or lobular carcinoma in situ (LCIS), were recommended to undergo surgical excision. For benign lesions with concordant imaging findings, the radiologist recommended US follow-up at 6, 12, and 24 months and mammographic follow-up at 12 and 24 months. If the lesions were highly suspicious despite benign pathologic results, surgical excision was recommended.

Data collection

Data relating to the biopsy procedure; core numbers, calcification retrieval and complications, the clinical information about whether the procedure was rebiopsy and whether the lesion was initially palpable, imaging findings, and Wi-UVAB and surgical pathological results were recorded. The reason to choose a Wi-UVAB device for biopsy was also recorded based on the original report. Imaging variables derived from the report were the maximum size of the lesion on US, which was identifiable, and the lesion type on mammography and US, and the Breast Imaging Reporting and Data System (BI-RADS) assessment category integrated with US and mammography. Calcification retrieval was considered satisfactory if four or more than four calcific particles were obtained.

We investigated the yield of Wi-UVAB along the lesion type on US and BI-RADS category on US. We compared the Wi-UVAB and final diagnosis with combination from the surgical pathologic (n = 81) and follow-up US findings obtained more than 6-month post-biopsy (n = 22). The underestimation rate was also analyzed. The DCIS underestimation rate was the percentage of the number of lesions surgically proven as IDC or microinvasive carcinoma among the lesions operated after the diagnosis of DCIS at biopsy. High-risk lesion underestimation rate was the percentage of the number of lesions surgically proven as any carcinoma (IDC, DCIS, or microinvasive carcinoma) among the lesions operated after the diagnosis of ADH or LCIS at biopsy. False-negative cases were defined as all breast cancers (invasive cancer and DCIS) with a benign diagnosis at biopsy. Discordant cases were defined as the lesions assessed as discordant among those with benign Wi-UVAB results. The imaging and clinical characteristics relating to the underestimation rates were evaluated using the Fisher’s exact test in categorical data and Student’s t-test in nonparametric data. Values of p < 0.05 were considered to indicate a statistically significant difference.

Statistical analyses were performed by using software (SPSS version 16.0; SPSS, Chicago, Ill and MedCalc; MedCalc, Mariakerke, Belgium).
Results

Data relating to the biopsy procedure

In 103 cases of 96 women, four or more cores were usually obtained (range, 4–25; average, 10). The number of biopsies performed per lesion was 4–25, with a mean of 10.

In 7 cases (6.8%), a biopsy was reattempted with a needle in situ after emptying and reinstallation of a collection cup, because specimen retrieval was unsatisfactory by visual inspection or specimen mammography. Eventually, successful specimen retrieval of an adequate amount was achieved in all cases. Mean core number obtained in these uneasy cases was 20, ranging from 18 to 25. Complications were recorded in 9 patients (9.4%). Bleeding was not controlled within 20 min of post-procedural compression. In 6 of these patients, bleeding during the procedure obscured the lesion. No further treatment was required beyond applying additional compression up to total 35 min. One of these patients complained of breast swelling during the subsequent 24 h but no specific treatment was instituted. No patient complained of severe pain. Also, none of patient experienced a vasovagal response or skin defects.

Specimen mammography was performed in 66 patients with mammographic calcifications and showed a satisfactory amount of calcifications in 56 cases. Among 10 cases (15.2%) with inadequate calcifications (three or fewer calcific particles), 7 were malignancies and 3 were benign. Eight cases (7 in malignancy, 1 in benign) underwent surgery. There was no underestimated case.

Metallic clips were inserted in 21 cases and preoperative localization using intra-lesional carbon marking or wire insertion were performed in 33 cases.

Clinical information and imaging findings

The major reason for using the Wi-UVAB device rather than the Tru-Cut biopsy gun was because the lesions were visible and suspicious but not apparent on US (n = 64). Minor reasons were that the lesion had a thin and slender shape (n = 8), small size (<7 mm; n = 18), lesion location near the implant (n = 2) or the chest wall muscle (n = 5), and biopsy intended for rebiopsy due to discordant benign results of 14-gauge core needle biopsy (n = 6). Most of the target lesions were nonpalpable (n = 96, 93.2%). Two of 7 palpable lesions were referred for rebiopsy and the remaining palpable lesion exhibited diffuse heterogeneity and calcifications on US (BI-RADS 4C and BI-RADS 4B, respectively). Six of 7 palpable lesions were confirmed to be malignant.

The lesion size on US was 0.4 to 5.1 cm (mean, 1.8 cm). The lesion type on mammography was calcifications in 66 cases (64.1%), masses, asymmetry or architectural distortion in 22 (21.4%), and negative findings in 15 (14.6%). The lesion type on US was a non-mass lesion with calcifications in 51 cases (49.5%), a non-mass lesion without calcifications in 18 (17.5%), a mass with calcifications in 8 (7.8%), and a mass without calcifications in 26 (25.2%) (Table 1). In 7 of 66 calcification cases on mammography, calcifications were not visible on US. The non-mass lesions appeared as non-uniform heterogeneous areas in 54 cases and duct-type tubular or branching lesions in 15. The integrated BI-RADS final assessment category was BI-RADS 4 in 97 lesions and BI-RADS 5 in 6 lesions. None of the lesions was BI-RADS \leq 3 (Table 1).

Pathological results

The histopathological diagnoses of the biopsy and surgical specimens are shown in Table 2. The malignancy rate was 64.1%. There were no significant difference between the malignancy rate in the lesions with calcifications and the rate in the lesions without calcifications (62.1% vs. 37.9%, respectively; p = 0.45). Among the 97 BI-RADS 4 lesions, the malignancy rate was
63.9% (Table 1). Among the six BI-RADS 5 lesions, 4 were malignant and 2 were high risk lesions. One of the high risk lesions classified as BI-RADS 5 was a pleomorphic LCIS that appeared as a tubular isoechoic lesion with microcalcifications on US. In this case, there were grouped pleomorphic calcifications on mammography (Fig 1). Final surgical pathology revealed pleomorphic LCIS. The other was ADH that presented as a faint non-mass lesion with microcalcifications on US that were segmental and fine pleomorphic on mammography. Final surgical result was DCIS.

There were 6 rebiopsy cases with imaging pathology discordance at initial Tru-cut core needle biopsy. Among them, 4 cases classified as BI-RADS 4B (n = 1) or 4C (n = 3) were upgraded to malignancy after rebiopsy. The other 2 BI-RADS 4A cases revealed stromal fibrosis.

Table 1. US Findings and BI-RADS classification in 103 Target Lesions of Wireless US-guided Vacuum-Assisted Biopsy in 96 Women.

|               | n (%) | Cancer, n (%) | High risk, n (%) | Benign, n (%) |
|---------------|-------|---------------|-----------------|--------------|
| **US findings** |       |               |                 |              |
| Non-mass lesion with calcifications | 51 (49.5%) | 36 (54.5%) | 4 (33.3%) | 9 (36.0%) |
| Non-mass lesion without calcifications | 18 (17.5%) | 9 (13.6) | 2 (16.7) | 7 (28.0) |
| Mass with calcification | 8 (7.8%) | 5 (7.6) | 4 (33.3) | 3 (12.0) |
| Mass without calcifications | 26 (25.2) | 16 (24.2) | 2 (16.7) | 6 (24.0) |
| **BI-RADS classification** |       |               |                 |              |
| BI-RADS Category 4 | 97 (94.2) | 62 (93.9) | 10 (83.3) | 25 (100) |
| 4A | 37 (35.9) | 14 (21.2) | 7 (58.3) | 16 (64.0) |
| 4B | 35 (34.0) | 25 (37.9) | 1 (8.3) | 9 (36.0) |
| 4C | 25 (24.3) | 23 (34.8) | 2 (16.7) | 0 (0.0) |
| BI-RADS Category 5 | 6 (5.8) | 4 (6.1) | 2 (16.7) | 0 (0.0) |
| **Total** | 103 (100.0) | 66 (64.1) | 12 (11.7) | 25 (24.3) |

doi:10.1371/journal.pone.0144046.t001

Table 2. Histologic Results of Wireless US-guided Vacuum-Assisted Biopsy (Wi-UVAB) and Surgical Biopsy in 103 Cases in 96 Women.

|                  | UVAB Histology (n = 103) | Surgical Histology (n = 81) | N/A |
|------------------|--------------------------|----------------------------|-----|
| **Malignancy (n = 66)** |                         |                            |     |
| IDC (18)         | IDC (18)                 |                            |     |
| MIBC (7)         | MIBC (4), IDC (3)       |                            |     |
| DCIS (40)        | DCIS (29)                | MIBC (9), Invasive cancer (2) |     |
| ILC (1)          | ILC (1)                 |                            |     |
| **High-risk lesions (n = 12)** |                      |                            |     |
| ADH or columnar cell change with atypia (7) | ADH (2) | DCIS (2) | Imaging follow up (3) |
| LCIS (3)         | LCIS (2)                 | ILC (1)                    |     |
| Intraductal papilloma with atypia (2) | Intraductal papilloma with atypia (2) | |     |
| **Benign lesions (n = 25)** | | | |
| Specific benign abnormality (12) | Lobulocentric granulomatous inflammation (1), Intraductal papilloma (1) | Imaging follow up (10) |
| Nonspecific benign abnormality (13) | Fibroadenoma(1), Nonspecific benign abnormality (3) | Imaging follow up (9) |

Number in parentheses are the number of the cases. MIBC, microinvasive breast carcinoma; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; N/A, Not available due to non-operation.

doi:10.1371/journal.pone.0144046.t002
All 66 malignant lesions underwent surgical biopsy; 11 of the 40 DCIS lesions revealed discordant final results (microinvasive ductal carcinoma, n = 9; invasive cancer, n = 2) (Table 2). Twelve lesions were high-risk lesions (ADH, n = 7; LCIS, n = 3; intraductal papilloma with atypia, n = 2). The 3 LCIS lesions were finally confirmed to be 2 LCIS and 1 ILC after the surgery. Among 7 ADH lesions, 2 proved to be DCIS (Table 2). The 3 patients with ADH lesions refused surgery and have been followed up with US and mammography (15 months and 19 months, respectively). These imaging findings demonstrated stability after 12 months.

Twenty-five lesions were benign (specific benign histology, n = 12; nonspecific benign histology, n = 13) (Table 2). The lesions with a specific benign histology included intraductal papilloma (n = 1), sclerosing adenosis (n = 4), fibroadenoma (n = 1), lobulocentric granulomatous inflammation (n = 1), diabetic mastopathy (n = 1), and columnar cell change (n = 4). The lesions with nonspecific benign histology included stromal fibrosis (n = 6) and fibrocystic change (n = 7). No repeat biopsy was required because of imaging and pathologic concordance. Follow-up imaging at >6 months (range, 6–18 months; mean, 10.1 months) showed no late development of malignancy in all benign lesions. There were neither false-negative nor
discordant cases that required additional diagnostic procedures in the cases with benign Wi-UVAB histology.

DCIS underestimation rate was 27.5% (11/40). Two DCIS lesions were upgraded to IDC; 1 was a 0.90-cm IDC and the other was a 0.14-cm mucinous carcinoma. Nine DCIS lesions upgraded to microinvasive ductal carcinoma. Most of the underestimated lesions (8/11) showed non-mass lesions with calcifications on US.

High risk lesion underestimation rate was 33.3% (3/9). One LCIS lesion proved to be ILC of 0.6 cm in 3.5 cm-sized LCIS (Fig 2), and 2 ADH cases revealed an 8-cm DCIS and a 0.5-cm DCIS, respectively. All high risk underestimated lesions revealed segmental or grouped pleomorphic calcification on mammography and non-mass lesion with calcifications on US.

Table 3 compares the accurate diagnoses (n = 67) and underestimations (n = 14) according to patient and lesion variables. No difference was found between the accurate diagnosis and underestimation groups in terms of age (p = 0.50), lesion size (p = 0.48), lesion type on US (p = 0.16), BI-RADS category (p = 0.28), number of core specimens (p = 0.23), or the number of calcification (p = 0.17).

**Discussion**

Percutaneous breast biopsies have transitioned from fine-needle aspiration biopsy to VAB, allowing for more accurate diagnosis of suspicious breast lesions and decreasing insufficient or inconclusive diagnoses. To obtain adequate tissue samples, Tru-Cut biopsy often requires repeated insertion and reinsertion of the needles through the lesion, causing patient discomfort and increasing the risk of complications [5].

Vacuum-assisted devices allow for single insertion with multiple contiguous samples to reduce non-diagnostic or ambiguous results and patient discomfort. However, it is quite bothersome for physicians to prepare and setup the large equipment of conventional VAB. A noteworthy advantage is that Wi-UVAB does not require additional time to prepare and setup the machine, allowing for biopsy to be promptly performed without delay. Wi-UVAB may offer easy scheduling with diagnostic US at the same day, differently from the conventional VAB. Also comparing with Tru-cut biopsy, Wi-UVAB does not require the time for in-and-out workout of the needle between samples, which can shorten the procedure time.

The reported complication rate associated with conventional vacuum-assisted devices ranges from 0% to 9%, and the most serious adverse events reported include severe bleeding and skin defects [6–9]. A recent study reported virtually no complications using the Wi-UVAB [5]. The present study also showed minimal complications; moderate amount of bleeding in 9 patients (9.4%) that lasted beyond the standard 10 min of postbiopsy manual compression. One of these patients complained of breast swelling during the subsequent 24 h but no specific treatment was instituted.

In a published study on the use of Wi-UVAB, most lesions exhibited opacities on mammography (70.6%), palpable nodes on US (74.6%), or a suspicious BI-RADS category (57.4%) [5]. In our study, most of the lesions were nonpalpable (93.2%), non-mass lesions with calcifications on US (49.5%), and all had a suspicious BI-RADS category (100.0%). In such case, VAB would be used rather than Tru-cut biopsy because an acquisition of representative samples by Tru-cut core needle biopsy is difficult as the lesions were broad with indistinct margins. US-guided biopsy may be preferable than stereotactic biopsy in terms of real-time, patient comfort, radiation exposure, procedure time, and cost effectiveness. Our study demonstrates that the Wi-UVAB device could be the device of choice for non-mass lesions because it allows fast acquisition of a large tissue volume resulting in high diagnostic accuracy of malignancy and does not necessarily require precise localization of the needle.
Tru-Cut core needle biopsy reportedly has a false-negative rate of 0% \([10–14]\) to 9% \([15, 16]\). Most studies with a false negative rate of 0% had small populations. \([10–12, 14]\) The absence of a false negative case in our study may also have resulted from the small number of benign cases. However, considering that four rebiopsy cases diagnosed benign lesion at core needle biopsy turned out to be malignant at Wi-UVAB, we can assume that the false-negative rate of Wi-UVAB is lower than that of Tru-cut biopsy due to the increased sample volume.

Presently, the high risk lesion underestimation rate was 33.3%, which is almost identical to the 31–33% reported in other Tru-cut biopsy studies. \([17, 18]\) The high risk breast lesions in our study were ADH, LCIS, and intraductal papilloma with atypia. These lesions are an indication for surgical excision because of a risk for malignancy.
ADH is a pathologic entity that has some, but not all features, of DCIS. Thus, sampling error can result in underestimation. In one study, the ADH underestimation rate was 18.8% as the complete removal of the lesion with the VAB. When the specimens were only partially collected from the lesions, the underestimation was 31.3%. In our study, half of ADH which underwent surgical excision upgraded to DCIS. Our high underestimation rate may be attributed to smaller size of needle (13-gauge) than conventional VAB (11-gauge), resulting in partial removal of the target lesions. However, the identification of ADH in a core biopsy specimen is clinically important because of the high prevalence of DCIS or invasive ductal carcinoma associated with this abnormality in as many as 56% of cases.

The present DCIS underestimation rate of 27.5% is lower than reported underestimation rate of Tru-Cut biopsy (39%-67%) and is similar with reported underestimation rate of VAB (17–41%). The lower DCIS underestimation rate with larger tissue acquisition devices is attributed to the larger volume of tissue acquired, with a decrease in sampling error. However, our DCIS underestimation lesions showed relative high proportion of microinvasive cancer (9/11). Underestimation rate for calcifications was reported to be significantly higher than that for masses. This difference might have resulted in a slightly higher proportion of microinvasive cancer in our study, because most of target lesions had visible but unapparent findings at the area of calcifications on US.

To identify possible factors involved in invasiveness, we compared the underestimated and accurately diagnosed groups; no statistically significant differences were evident between the groups with regard to clinical and imaging characteristics.

Underestimation has been reported as being more frequent when 10 or fewer specimens were obtained. However, the core number was not statistically different between the underestimated and accurately diagnosed groups (p = 0.23) in our study. The mean core number of reattempted biopsy cases was two times higher than that of other cases. We assume that the

| Feature                      | Accurately Diagnosed (n = 67) | Underestimated (n = 14) | p     |
|------------------------------|-------------------------------|------------------------|-------|
| Mean ± SD patient age (year) | 50.3 ± 8.9                    | 54.5 ± 10.1            | 0.50  |
| Mean ± SD lesion size (cm)   | 1.8 ± 1.2                     | 2.3 ± 1.4              | 0.48  |
| Lesion type on US            |                               |                        | 0.16  |
| Non-mass lesion with calcifications | 33                      | 10                      |       |
| Non-mass lesion without calcifications | 12                      | 1                       |       |
| Mass with calcification      | 4                             | 2                       |       |
| Mass without calcifications  | 18                            | 1                       |       |
| BI-RADS category             |                               |                        | 0.28  |
| 4                            | 63                            | 12                      |       |
| 5                            | 4                             | 2                       |       |
| No. of specimen              |                               |                        | 0.23  |
| ≤ 5                          | 11                            | 0                       |       |
| 6–10                         | 31                            | 7                       |       |
| ≥ 11                         | 25                            | 7                       |       |
| No. of calcification         |                               |                        | 0.17  |
| ≥ 4                          | 29                            | 12                      |       |
| < 4                          | 8                             | 0                       |       |

P values were calculated by student T-test and fisher’s exact test.

doi:10.1371/journal.pone.0144046.t003
number of core obtained may not reflect the degree of thoroughness of sampling; instead, a
greater number of cores may indicate an initial failure to retrieve sufficient samples.

Another recent study showed that DCIS underestimation rate was significantly related to
presence of palpability, mass and calcification by US and biopsy method.[26] Lesions >20 mm
in size have been associated with invasive components on final pathology. [27] However, in
our study, there was no significant difference between underestimated and accurate diagnosed
lesion group in terms of lesion size, retrieval of calcification, and ultrasonographic features of lesions,
such as mass or non-mass.

Our study had several limitations. First, the sample size of benign and high risk lesion was
relatively small. False negative rate and high risk underestimation rate may influenced by the
sample size. Second, there were cases that did not undergo surgical excision to confirm the
final pathology, even though the lesions showed stability on US follow-up (range, 6–20; mean
11.1 months). A change could be possible afterwards. Third, in our study, only experts carried
out the biopsies. If physicians lack experience with Wi-UVAB, training is required to obtain
acceptable false negative and underestimation rates with relatively few complications from the
procedure.

In conclusion, we believe that this Wi-UVAB device is safe and accurate. It is useful when
US-guided biopsies are preferred and when suspicious nonpalpable, non-mass lesions exhibit
visible but unapparent calcifications on US. Although the histological results of DCIS may be
upgraded to subcentimeter invasive cancer or microinvasive ductal carcinoma and high risk
lesion may turn out to be malignancy, false-negative biopsy results can be avoided by use of
Wi-UVAB.

Author Contributions

Conceived and designed the experiments: ERC BKH. Performed the experiments: ERC BKH
ESK EYK JSC EYC SJN. Analyzed the data: ERC BKH. Contributed reagents/materials/analysis
tools: ERC BKH. Wrote the paper: ERC BKH.

References

1. Brem RF, Behrndt VS, Sanow L, Gatewood OM. Atypical ductal hyperplasia: histologic underestimation
   of carcinoma in tissue harvested from impalpable breast lesions using 11-gauge stereotactically guided
directional vacuum-assisted biopsy. AJR Am J Roentgenol. 1999; 172(5):1405–7. Epub 1999/05/05.
doi: 10.2214/ajr.172.5.10227526 PMID: 10227526.
2. Lee SH, Kim EK, Kim MJ, Moon HJ, Yoon JH. Vacuum-assisted breast biopsy under ultrasonographic
guidance: analysis of a 10-year experience. Ultrasonography. 2014. Epub 2014/07/19. doi:10.14366/
usg.14020 PMID: 25036755.
3. Philpotts LE, Lee CH, Horvath LJ, Lange RC, Carter D, Tocino I. Underestimation of Breast Cancer
   with II-Gauge Vacuum Suction Biopsy. American Journal of Roentgenology. 2000; 175(4):1047–50.
doi: 10.2214/ajr.175.4.1751047 PMID: 11000162
4. Rosenblatt R, Fineberg SA, Sparano JA, Kaleya RN. Stereotactic core needle biopsy of multiple sites
   in the breast: efficacy and effect on patient care. Radiology. 1996; 201(1):67–70. Epub 1996/10/01. doi:
   10.1148/radiology.201.1.8615522 PMID: 8615522.
5. Bagnera S, Patarina S, Milanesio L, Gatti G, Orlassino R. New Wireless Handheld Ultrasound-Guided
   Vacuum-Assisted Breast Biopsy (VABB) Devices: An Important Innovation in Breast Diagnosis. Open
   Journal of Radiology. 2013; 03(04):174–9.
6. Schueller G, Schueller-Weidekamm C, Helbich TH. Accuracy of ultrasound-guided, large-core needle
   breast biopsy. Eur Radiol. 2008; 18(9):1761–73. Epub 2008/04/17. doi: 10.1007/s00330-008-0955-4
   PMID: 18414872.
7. Perez-Fuentes JA, Longobardi IR, Acosta VF, Marin CE, Liberman L. Sonographically guided direc-
tional vacuum-assisted breast biopsy: preliminary experience in Venezuela. AJR Am J Roentgenol.
   2001; 177(6):1459–63. Epub 2001/11/22. doi: 10.2214/ajr.177.6.1771459 PMID: 11717107.
8. Parker SH, Klaus AJ, McWey PJ, Schilling KJ, Dukesne N, et al. Sonographically guided directional vacuum-assisted breast biopsy using a handheld device. AJR Am J Roentgenol. 2001; 177(2):405–8. Epub 2001/07/20. doi: 10.2214/ajr.177.2.1770405 PMID: 11461871.

9. Fine RE, Boyd BA, Whitworth PW, Kim JA, Harness JK, Burak WE. Percutaneous removal of benign breast masses using a vacuum-assisted hand-held device with ultrasound guidance. Am J Surg. 2002; 184(4):332–6. Epub 2002/10/18. PMID: 12383895.

10. Schoonjans JM, Brem RF. Fourteen-gauge ultrasonographically guided large-core needle biopsy of breast masses. J Ultrasound Med. 2001; 20(9):967–72. Epub 2001/09/11. PMID: 11549157.

11. Parker SH, Jobe WE, Dennis MA, Stavros AT, Johnson KK, Yakes WF, et al. US-guided automated large-core breast biopsy. Radiology. 1993; 187(2):507–11. Epub 1993/05/01. doi: 10.1148/radiology.187.2.8475299 PMID: 8475299.

12. Helbich TH, Mayr W, Schick S, Youssefzadeh S, Rudas M, Taucher S, et al. Coaxial technique: approach to breast core biopsies. Radiology. 1997; 203(3):884–90. Epub 1997/06/01. doi: 10.1148/radiology.203.3.9169689 PMID: 9169689.

13. Parker SH, Burbank F, Jackman RJ, Aucreman CJ, Cardenosa G, Cink TM, et al. Percutaneous large-core breast biopsy: a multi-institutional study. Radiology. 1994; 193(2):359–64. Epub 1994/11/01. doi: 10.1148/radiology.193.2.7972743 PMID: 7972743.

14. Smith DN, Rosenfield Darling ML, Meyer JE, Denison CM, Rose DJ, Lester S, et al. The utility of ultrasound-guided large-core needle biopsy: results from 500 consecutive breast biopsies. Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine. 2001; 20(1):43–9. Epub 2001/01/10. PMID: 11149527.

15. Memarsadeghi M, Pfarl G, Riedl C, Wagner T, Rudas M, Helbich TH. [Value of 14-gauge ultrasound-guided large-core needle biopsy of breast lesions: own results in comparison with the literature]. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2003; 175(3):374–80. Epub 2003/03/14. doi: 10.1055/s-2003-37822 PMID: 12635014.

16. Schulz-Wendtland R, Kramer S, Lang N, Bautz W. Ultrasound guided microbiopsy in mammary diagno sis: indications, technique and results. Anticancer research. 1998; 18(3c):2145–6. Epub 1998/08/15. PMID: 9703772.

17. Pijnappel RM, van den Donk M, Holland R, Mali WP, Peterse JL, Hendriks JH, et al. Diagnostic accuracy for different strategies of image-guided breast intervention in cases of nonpalpable breast lesions. British journal of cancer. 2004; 90(3):595–600. Epub 2004/02/05. doi: 10.1038/sj.bjc.6601559 PMID: 14760370; PubMed Central PMCID: PMC3405951.

18. Schueller G, Janamis M, Ponhold L, Fuchsjaeger M, Memarsadeghi M, Rudas M, et al. US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases. Radiology. 2008; 248(2):406–13. Epub 2008/07/22. doi: 10.1148/radiol.2482071994 PMID: 18641246.

19. Lourenco AP, Mainiero MB, Lazarus E, Giri D, Schepps B. Stereotactic breast biopsy: comparison of histologic underestimation rates with 11- and 9-gauge vacuum-assisted breast biopsy. AJR American journal of roentgenology. 2007; 189(5):W275–9. Epub 2007/10/24. doi: 10.2214/ajr.07.2165 PMID: 17954625.

20. Helbich TH, Buchberger W, Rudas M. [Stereotactically and sonographically guided vacuum-assisted breast biopsy: a national consensus for Austria]. Rofo. 2002; 174(4):517–22. Epub 2002/12/06. PMID: 12465616.

21. Liberman L, Cohen MA, Dershaw DD, Abramson AF, Hann LE, Rosen PP. Atypical ductal hyperplasia diagnosed at stereotactic core biopsy of breast lesions: an indication for surgical biopsy. AJR American journal of roentgenology. 1995; 164(5):1111–3. Epub 1995/05/01. doi: 10.2214/ajr.164.5.7717215 PMID: 7717215.

22. Cassano E, Urban LA, Pizzamiglio M, Abbate F, Maisonneuve P, Renne G, et al. Ultrasound-guided vacuum-assisted core breast biopsy: experience with 406 cases. Breast Cancer Res Treat. 2007; 102(1):103–10. Epub 2006/07/14. doi: 10.1007/s10549-006-9305-x PMID: 16838109.

23. Cho N, Moon WK, Cha JH, Kim SM, Kim SJ, Lee SH, et al. Sonographically guided core biopsy of the breast: comparison of 14-gauge automated gun and 11-gauge directional vacuum-assisted biopsy methods. Korean journal of radiology. 2005; (6):102–9. Epub 2005/06/22. PMID: 15968148; PubMed Central PMCID: PMC2686400.

24. Youk JH, Kim EK, Kim MJ, Oh KK. Sonographically guided 14-gauge needle biopsy of breast masses: a review of 2,420 cases with long-term follow-up. AJR Am J Roentgenol. 2008; 190(1):202–7. Epub 2007/12/21. doi: 10.2214/ajr.07.2419 PMID: 18094312.

25. Jackman RJ, Burbank F, Parker SH, Evans WP 3rd, Lechner MC, Richardson TR, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology. 2001; 218(2):497–502. Epub 2001/02/13. doi: 10.1148/radiology.218.2.r01fe35497 PMID: 11161168.
26. Park HS, Kim HY, Park S, Kim EK, Kim SI, Park BW. A nomogram for predicting underestimation of invasiveness in ductal carcinoma in situ diagnosed by preoperative needle biopsy. Breast (Edinburgh, Scotland). 2013; 22(5):869–73. Epub 2013/04/23. doi: 10.1016/j.breast.2013.03.009 PMID: 23601760.

27. Lee JW, Han W, Ko E, Cho J, Kim EK, Jung SY, et al. Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. Journal of surgical oncology. 2008; 98(1):15–20. Epub 2008/05/07. doi: 10.1002/jso.21077 PMID: 18459155.